PRR22 and cancer: Further analysis suggested that modulation of angiogenesis-related genes (including ANGPTL4, FN1, HSPG2, SRPX2, KLK5, L1CAM, Prr22, FOXJ1, IL24, and TRIM54) potentially contributes to anlotinib resistance (Figures 2D,E, Tables S3, S4), as anlotinib is a multi-targeted anti-angiogenesis drug for cancer therapy (8–10, 12, 23).